CA3206537A1 - Use of neuroactive steroids for treatment of sexual dysfunction - Google Patents

Use of neuroactive steroids for treatment of sexual dysfunction

Info

Publication number
CA3206537A1
CA3206537A1 CA3206537A CA3206537A CA3206537A1 CA 3206537 A1 CA3206537 A1 CA 3206537A1 CA 3206537 A CA3206537 A CA 3206537A CA 3206537 A CA3206537 A CA 3206537A CA 3206537 A1 CA3206537 A1 CA 3206537A1
Authority
CA
Canada
Prior art keywords
compound
pharmaceutically acceptable
administered
acceptable salt
sexual
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3206537A
Other languages
English (en)
French (fr)
Inventor
Vijayveer BONTHAPALLY
Ellison SUTHOFF
Handan GUNDUZ-BRUCE
Ryan ARNOLD
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sage Therapeutics Inc
Original Assignee
Sage Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics Inc filed Critical Sage Therapeutics Inc
Publication of CA3206537A1 publication Critical patent/CA3206537A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
CA3206537A 2021-01-28 2022-01-27 Use of neuroactive steroids for treatment of sexual dysfunction Pending CA3206537A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163142840P 2021-01-28 2021-01-28
US202163142833P 2021-01-28 2021-01-28
US63/142,833 2021-01-28
US63/142,840 2021-01-28
PCT/US2022/014075 WO2022165017A1 (en) 2021-01-28 2022-01-27 Use of neuroactive steroids for treatment of sexual dysfunction

Publications (1)

Publication Number Publication Date
CA3206537A1 true CA3206537A1 (en) 2022-08-04

Family

ID=80787167

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3206537A Pending CA3206537A1 (en) 2021-01-28 2022-01-27 Use of neuroactive steroids for treatment of sexual dysfunction

Country Status (9)

Country Link
US (1) US20240122945A1 (https=)
EP (1) EP4284382A1 (https=)
JP (1) JP2024507638A (https=)
KR (1) KR20230136599A (https=)
AU (1) AU2022214187A1 (https=)
CA (1) CA3206537A1 (https=)
IL (1) IL304080A (https=)
MX (1) MX2023008726A (https=)
WO (1) WO2022165017A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2882708A1 (en) 2012-08-21 2014-02-27 Sage Therapeutics, Inc. Methods of treating epilepsy or status epilepticus
KR102396328B1 (ko) 2013-04-17 2022-05-10 세이지 테라퓨틱스, 인크. 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
WO2016082789A1 (en) 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
EP3504189A1 (en) 2016-08-23 2019-07-03 Sage Therapeutics, Inc. A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid
MA51046A (fr) 2017-12-08 2021-03-17 Sage Therapeutics Inc Dérivés de 21-[4-cyano-pyrazol-1-yl]-19-nor-pregan-3. alpha-ol-20-one deutérés pour le traitement de troubles du snc
PE20240780A1 (es) * 2021-07-28 2024-04-17 Sage Therapeutics Inc Formas cristalinas de un esteroide neuroactivo

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200801081A1 (ru) * 2005-10-14 2008-10-30 Х. Лундбекк А/С Способы лечения расстройств центральной нервной системы комбинацией малых доз эсциталопрама и бупропиона
KR102396328B1 (ko) 2013-04-17 2022-05-10 세이지 테라퓨틱스, 인크. 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법
EP3068226A4 (en) * 2013-11-11 2017-05-17 Euthymics Bioscience, Inc. Novel methods
ES2805598T3 (es) 2014-05-29 2021-02-12 Sage Therapeutics Inc Esteroides neuroactivos, composiciones y usos de los mismos
KR20240157128A (ko) * 2016-03-08 2024-10-31 세이지 테라퓨틱스, 인크. 신경활성 스테로이드, 조성물, 및 그의 용도
EP3504189A1 (en) 2016-08-23 2019-07-03 Sage Therapeutics, Inc. A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid
CA3103421A1 (en) * 2018-06-12 2019-12-19 Sage Therapeutics, Inc. A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof
US20220125803A1 (en) * 2019-03-04 2022-04-28 Praxis Precision Medicines, Inc. Methods for the treatment of perimenopause and menopause

Also Published As

Publication number Publication date
JP2024507638A (ja) 2024-02-21
IL304080A (en) 2023-08-01
MX2023008726A (es) 2023-12-14
KR20230136599A (ko) 2023-09-26
AU2022214187A1 (en) 2023-07-13
US20240122945A1 (en) 2024-04-18
AU2022214187A9 (en) 2024-05-23
EP4284382A1 (en) 2023-12-06
WO2022165017A1 (en) 2022-08-04

Similar Documents

Publication Publication Date Title
US20240122945A1 (en) Use of neuroactive steroids for treatment of sexual dysfunction
WO2022177718A1 (en) Use of neuroactive steroid for treatment of sexual dysfunction
US12409176B2 (en) Methods of treating acute depression
US8309535B2 (en) Compositions and methods to treat recurrent medical conditions
CZ99597A3 (en) Use of combination of tricyclic or tetracyclic antidepressant, inhibitor of serotonin recatching or inhibitor of monoaminooxidase with a compound inducing neurotransmitter or with a neurotransmitter precursor for preparing a medicament for treating or prevention of sclerosis multiplex or other demyelinisation states
JP2023511370A5 (https=)
JP2019515891A (ja) タンニン酸を含有する組成物及びその使用
JP2021080286A (ja) 神経筋疾患、神経変性疾患、自己免疫疾患、発達疾患および／または代謝疾患の処置のための、脳由来神経栄養因子（ｂｄｎｆ）の誘導された発現
KR20230131927A (ko) 신경 정신 질환에 대한 항우울제와 덱스트로메토르판의조합
WO2012070043A1 (en) Method and composition for weight-gain management
KR20250004125A (ko) 우울증을 치료하기 위한 nk-1 길항제 조성물 및 우울증 치료에 사용하는 방법
CN111973592A (zh) 治疗肌萎缩侧索硬化和神经病的方法
KR102793974B1 (ko) 우울증을 치료하기 위한 약제학적 조성물
US11801256B2 (en) Antidepressant-psilocybin co-treatment to assist psychotherapy
CZ301210B6 (cs) Použití desoxypeganinu k ošetrování klinické deprese
CN116847852A (zh) 神经活性类固醇治疗性功能障碍的用途
US20140148465A1 (en) Compositions and Methods to Improve Treatment of Medical Conditions Using D-Cycloserine
TWI922961B (zh) 用於治療抑鬱症之組合物及方法
MXPA01001178A (es) Metodos y composiciones para tratamiento y la prevencion de ciertos trastornos psiquiatricos y medicos mediante el empleo de la moclobemida.
HK40100385A (zh) 用於神经精神病症的抗抑郁剂和右美沙芬的组合
HK40060077A (en) Domperidone compositions and methods for treating depression
Cole NEW THERAPEUTIC DIRECTIONS: PRESENTATIONS FROM THE MOVEMENT DISORDER SOCIETY'S 13TH INTERNATIONAL CONGRESS OF PARKINSON'S DISEASE AND MOVEMENT DISORDERS

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241219

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241219

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241219

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251205

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251205

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20260126

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20260126

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260126

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R11-R103 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF NAME REQUEST RECEIVED

Effective date: 20260203